Viracta Therapeutics Inc. (VIRX)
0.16
-0.01 (-5.83%)
At close: Jan 15, 2025, 2:44 PM
undefined% (undefined)
| Bid | 0.16 |
| Market Cap | 6.55M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.17 |
| Volume | 618,497 |
| Avg. Volume (20D) | 2,875,839 |
| Open | 0.18 |
| Previous Close | 0.17 |
| Day's Range | 0.15 - 0.18 |
| 52-Week Range | 0.13 - 1.31 |
| Beta | undefined |
About VIRX
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as we...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 27, 2005
Employees 40
Stock Exchange NASDAQ
Ticker Symbol VIRX
Website https://www.viracta.com
Analyst Forecast
According to 4 analyst ratings, the average rating for VIRX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 1719.28% from the latest price.
Buy 75.00%
Hold 25.00%
Sell 0.00%
5 months ago ·
Source
-11.76%
Viracta Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
9 months ago ·
Source
-32.17%
Viracta Therapeutics shares are trading lower. The company announced topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from both arms of the relapsed or refractory Epstein-Barr virus-positive peripheral T-cell lymphoma cohort.
